Singatera is a personalized, tumor-informed assay for ultra sensitive detection of molecular residual disease (MRD). Signatera can be used in all solid tumor types.
Signatera answers the questions:

• Is there residual disease?
• Is the treatment working?
• Is the tumor truly progressing?
• Is there a need to change or reinitiate the treatment?